SENSEX NIFTY

Celltrion

Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

Photos »

  /  
USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Messages on Celltrion »

koppik

Gold Member

11 Followers

Biocon  

Teva Pharmaceutical Industries, an Israeli genetic drug maker, said it may consider buying South Korean pharmaceutical firm Celltrion as an option to strengthen its biosimilar portfolio. http://t.in.com/03Wd

4.51 PM Oct 17th 2016

huensang

New Member

0 Follower

Biocon  

sandoz,celltrion & Samsung bioepis...

3.42 PM Aug 31st 2016

Willwin

Platinum Member

1126 Followers

Biocon  

GlobeNewswirelogo Global Biosimilars Market to Grow at a CAGR of 55.52% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Biocon, Celltrion, Dr Reddy`s

9.20 PM Aug 25th 2016

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.